GlassScriptPhysician profile
Ashley L Vize
NPI 1295973147
$4,076.63
in general payments reported to CMS, 2019-2025
31 companies · $269 in 2025
The $269 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,419 · 2022: $990 · 2023: $741 · 2024: $659 · 2025: $269.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,668.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,668.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $886.21 | 2021-2025 | |
| Glaxosmithkline, LLC. | $664.62 | 2021-2025 | Trelegy Ellipta |
| Lilly USA, LLC | $503.37 | 2021-2025 | Mounjaro, Zepbound |
| Novo Nordisk INC | $453.63 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $221.69 | 2021-2025 | Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $193.78 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $128.60 | 2022 | |
| Pfizer INC. | $124.71 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $95.82 | 2021-2024 | Breztri, Airsupra |
| Abbott Laboratories | $77.06 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $70.77 | 2021 | |
| Dexcom, INC. | $69.33 | 2022-2023 | Dexcom G6 Transmitter |
| Esperion Therapeutics, INC. | $61.01 | 2021 | |
| Exact Sciences Corporation | $58.72 | 2023-2024 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $55.40 | 2021-2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $52.96 | 2025 | Caplyta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $43.78 | 2021-2025 | Xifaxan |
| Kowa Pharmaceuticals America, INC. | $37.43 | 2021-2022 | |
| Phathom Pharmaceuticals, INC. | $36.47 | 2024 | Voquezna |
| Amarin Pharma, INC. | $32.01 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $29.59 | 2022 | |
| Novartis Pharmaceuticals Corporation | $27.34 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $23.35 | 2023 | |
| Daiichi Sankyo INC. | $21.86 | 2023 | Injectafer |
| Astellas Pharma US INC | $18.93 | 2021 | |
| Evoke Pharma, INC. | $18.73 | 2025 | |
| Bausch Health US, LLC | $17.87 | 2021 | |
| Ironwood Pharmaceuticals, INC | $16.14 | 2023 | Linzess |
| Corcept Therapeutics | $14.31 | 2025 | Korlym |
| Teva Pharmaceuticals USA, INC. | $13.43 | 2021 | |
| Genentech USA, INC. | $7.71 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Vize listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.